R. L. Batey, M.D.; L. J. Lieberman, M.D.; R. S. Eliot, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Digitalis-induced cardiac arrhythmias remain a significant therapeutic problem. Recently beta-adrenergic blocking agents have been used. However, although propranolol suppresses certain types of supraventricular arrhythmias resulting from over-digitalization, it has not been shown to be equally effective in suppressing ventricular arrhythmias. The cardiovascular effects of a new beta-adrenergic blocking agent, alprenolol, (Aptine®, Astra Pharmaceutical Products, Inc., Worcester, Mass.), are similar to propranolol. The major difference is that alprenolol has a direct cardiac beta-adrenergic effect This additional effect should theoretically reduce the incidepce and degree of severe bradycardia, hypotension, and heart failure. Alprenolol was used in nine instances of digitalis-induced ventricular arrhythmias.
Batey RL, Lieberman LJ, Eliot RS. Alprenolol: An Effective Beta Blocker for Digitalis-Induced Ventricular Arrhythmias.. Ann Intern Med. ;72:778. doi: 10.7326/0003-4819-72-5-778_3
Download citation file:
Published: Ann Intern Med. 1970;72(5):778.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use